Dr. Weiss on Immunotherapy Combinations in Head and Neck Cancer

Jared Weiss, MD
Published: Tuesday, Jul 25, 2017



Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.

In addition to the approved PD-1 agents, PD-L1 agents will soon be used in the recurrent metastatic setting, says Weiss. Data with combinations of CTLA-4 agents such as ipilimumab (Yervoy) and nivolumab (Opdivo) or durvalumab (Imfinzi) and tremelimumab will be reported in the coming months, as well.

The combination of PD-1 and IDO inhibitors is also showing promise, Weiss says.
 
SELECTED
LANGUAGE


Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses immunotherapy combinations in head and neck cancer.

In addition to the approved PD-1 agents, PD-L1 agents will soon be used in the recurrent metastatic setting, says Weiss. Data with combinations of CTLA-4 agents such as ipilimumab (Yervoy) and nivolumab (Opdivo) or durvalumab (Imfinzi) and tremelimumab will be reported in the coming months, as well.

The combination of PD-1 and IDO inhibitors is also showing promise, Weiss says.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Publication Bottom Border
Border Publication
x